干扰素联合化疗治疗晚期原发肝癌31例  

Clinical research of interferon with chemotherapy regimen for advanced primary liver

作　　者：邝先奎 朱项临 司小山 李林 许莉[2] 

机构地区：[1]项城市第一人民医院肿瘤科,河南项城466200 [2]郑州大学一附院肿瘤科,河南郑州450052

出　　处：《中国医药导报》2008年第5期56-57,共2页China Medical Herald

摘　　要：目的:观察干扰素联合化疗治疗晚期原发肝癌的疗效。方法:58例晚期原发肝癌随机分为对照组和观察组,对照组采用ADF方案:阿霉素(ADM)40～50 mg,d1,顺铂(DDP)20 mg,d1～5,5-氟尿嘧啶(5-FU)500 mg,d1～5;观察组在此基础上加用干扰素6 000 000 U,皮下注射,隔日1次,连用4～6周。结果:观察组:PR16%(5/31),NC25%(8/31),(PR+NC)41%;一年生存率22.5%(8/31),中位生存期32周;对照组:PR11%(3/27),NC18%(5/27),(PR+NC)29%。一年生存率14.8%(4/27),中位生存期28周。两组相比,P<0.05。结论:干扰素联合化疗可以提高晚期原发肝癌的疗效。Objective：To observe the effects of interferon with chemotherapy for patients with advanced primary liver. Methods： 58 patients were divided into two groups,one group that treated with ADM 40-50 mg d1,DDP 20 mg d1-5,5-FU 500 mg,d1-5;the second group added the interferon 6 000 000 U,qod,in 4-6 weeks.Results：The one group：PR16%（5/31）, NC25% （8/31 ）, （PR＋NC）41% ;the one year survival rate was 22.5% （8/31 ）,the median survival was 32 weeks ;the second group ： PR11% （3/27）, NC 18% （5/27）, （PR＋NC）29%.The one year survival rate was 14.8% （4/27）, the median survival was 28 weeks.P〈0.05.Conelusion：Clinieal research of interferon with chemotherapy regimen may further increase the therapeutic effects for advanced primary liver.

关 键 词：干扰素 晚期原发肝癌 化疗 

分 类 号：R735.7[医药卫生—肿瘤]